Aimmune’s PALFORZIA obtains EC’s approval for treating peanut allergies

Author : Saipriya Iyer | Published Date : 2020-12-22 

In recent developments, U.S.-based biopharmaceutical company Aimmune Therapeutics Inc. has reportedly received approval from the European Commission (EC) for using its oral immunotherapy, PALFORZIA to treat individuals with peanut allergy.

For the uninitiated, PALFORZIA is a biologic drug that is administered with a systematic dosage approach based on oral immunotherapy (OIT). The process involves the initial ingestion of the specific allergenic proteins in small quantities followed by a gradual increment in the amount to mitigate allergic reactions to the allergen. Furthermore, the drug is produced from a defatted powder of Arachis hypogaea L and is indicated in patients between the age of 4 to 17 years.

The recent development comes after two successful phases 3 clinical trials of the drug, namely Artemis and Palisade, cited sources with relevant information. The oral immunotherapy, in both the trials, met the primary objective and outperformed the placebo results.

President and CEO of Aimmune Therapeutics, Andrew Oxtoby was reported saying that the European Commission’s approval of the treatment is a significant milestone for the company. The company will now focus on launching the product in the United Kingdom and Germany in May 2021, he added.

Meanwhile, Greg Behar, CEO of Nestlé Health Science S.A., commented that the EC approval is the first treatment approved for peanut allergy in the European Union.

Reportedly, around 17 million people across Europe are affected by food allergies, among which peanut allergy is of the highest prevalence. Approximately 1.6% of European children develop the allergy at an early stage and are subject to life-threatening symptoms.

About Aimmune Therapeutics Inc.

Aimmune Therapeutics is a subsidiary of Nestlé Health Science S.A that functions as a clinical-stage biopharmaceutical firm. The California-headquartered organization focuses on commercializing and developing treatments for potentially life-threatening food allergies as well as other food-mediated ailments, primarily gastrointestinal conditions.

Source credits –


About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Ramping production of lithium-ion batteries to accelerate tert-amylbenzene demand in Asia Pacific

Published Date: 2021-01-05         Author: Saipriya Iyer

As an active pharmaceutical ingredient (API) used in various clinical products to being used as an electronic additive in the making of lithium-ion batteries, tert amylbenzene (TAB) has gained wide-spread recognition across diverse industries. The chemical substance acts as a crucial intermediate in... Read More

FMCG firms to explore oral care market amidst rising hygiene concerns

Published Date: 2021-01-04         Author: Saipriya Iyer

Fast-moving consumer goods businesses in India are reportedly expanding their range of oral care, joining new and niche categories including mouthwashes, ayurvedic mouth cleansers, and mouth sprays as customer issues around general hygiene persists. For the record, Dabur India and Colgate Palmoli... Read More

Microsoft to introduce ‘Google assistant’ alternative for Windows

Published Date: 2020-12-28         Author: Saipriya Iyer

Microsoft Corporation, an American multinational technology giant, is reportedly testing a new voice launcher feature which will enable users to interact with files and applications using voice commands. According to trusted sources, the feature is currently available to select group of users who... Read More

© 2022 Fractovia. All Rights Reserved